Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis.

Shapira S, Leshno A, Katz D, Maharshak N, Hevroni G, Jean-David M, Kraus S, Galazan L, Aroch I, Kazanov D, Hallack A, Becker S, Umanski M, Moshkowitz M, Dotan I, Arber N.

Therap Adv Gastroenterol. 2017 Nov 28;11:1756283X17741864. doi: 10.1177/1756283X17741864. eCollection 2018.

2.

Selective eradication of cancer cells by delivery of adenovirus-based toxins.

Shapira S, Shapira A, Kazanov D, Hevroni G, Kraus S, Arber N.

Oncotarget. 2017 Jun 13;8(24):38581-38591. doi: 10.18632/oncotarget.16934.

3.

Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers.

Shapira S, Pleban S, Kazanov D, Tirosh P, Arber N.

PLoS One. 2016 Jun 8;11(6):e0156540. doi: 10.1371/journal.pone.0156540. eCollection 2016.

4.

III-nitride tunable cup-cavities supporting quasi whispering gallery modes from ultraviolet to infrared.

Shubina TV, Pozina G, Jmerik VN, Davydov VY, Hemmingsson C, Andrianov AV, Kazanov DR, Ivanov SV.

Sci Rep. 2015 Dec 11;5:17970. doi: 10.1038/srep17970.

5.

Delayed Wound Healing in Heat Stable Antigen (HSA/CD24)-Deficient Mice.

Shapira S, Ben-Amotz O, Sher O, Kazanov D, Mashiah J, Kraus S, Gur E, Arber N.

PLoS One. 2015 Oct 6;10(10):e0139787. doi: 10.1371/journal.pone.0139787. eCollection 2015.

6.

CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome.

Shamai S, Nabiochtchikov I, Kraus S, Zigdon S, Kazanov D, Itzhak-Klutch M, Eizner C, Arber N, Geva R.

PLoS One. 2015 Sep 22;10(9):e0134469. doi: 10.1371/journal.pone.0134469. eCollection 2015.

7.

Predictive Levels of CD24 in Peripheral Blood Leukocytes for the Early Detection of Colorectal Adenomas and Adenocarcinomas.

Kraus S, Shapira S, Kazanov D, Naumov I, Moshkowitz M, Santo E, Galazan L, Geva R, Shmueli E, Hallack A, Arber N.

Dis Markers. 2015;2015:916098. doi: 10.1155/2015/916098. Epub 2015 May 11.

8.

Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice.

Kraus S, Naumov I, Shapira S, Kazanov D, Aroch I, Afek A, Eisenberg O, George J, Arber N, Finkelstein A.

Isr Med Assoc J. 2014 Apr;16(4):233-8.

9.

Role of CD24 polymorphisms in the susceptibility to inflammatory bowel disease.

Lisiansky V, Kraus S, Naumov I, Kazanov D, Nabiochtchikov I, Toledano O, Leshno M, Avivi D, Dotan I, Arber N, Moshkowitz M.

Int J Biol Markers. 2014 Mar 24;29(1):e62-8. doi: 10.5301/jbm.5000072.

PMID:
24557789
10.

CD24 knockout prevents colorectal cancer in chemically induced colon carcinogenesis and in APC(Min)/CD24 double knockout transgenic mice.

Naumov I, Zilberberg A, Shapira S, Avivi D, Kazanov D, Rosin-Arbesfeld R, Arber N, Kraus S.

Int J Cancer. 2014 Sep 1;135(5):1048-59. doi: 10.1002/ijc.28762. Epub 2014 Mar 21.

11.

CD24 gene polymorphism--a novel prognostic factor in esophageal cancer.

Sadot E, Kraus S, Stein M, Naboishchikov I, Toledano O, Kazanov D, Arber N, Kashtan H.

Int J Biol Markers. 2014 Mar 24;29(1):e49-54. doi: 10.5301/jbm.5000071.

PMID:
24474454
12.

The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews.

Boursi B, Sella T, Liberman E, Shapira S, David M, Kazanov D, Arber N, Kraus S.

Eur J Cancer. 2013 Nov;49(17):3680-5. doi: 10.1016/j.ejca.2013.06.040. Epub 2013 Jul 26.

PMID:
23896379
13.

Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.

Kraus S, Hummler S, Toriola AT, Poole EM, Scherer D, Kotzmann J, Makar KW, Kazanov D, Galazan L, Naumov I, Coghill AE, Duggan D, Gigic B, Arber N, Ulrich CM.

Pharmacogenet Genomics. 2013 Aug;23(8):428-437. doi: 10.1097/FPC.0b013e3283631784.

14.

One stop screening for multiple cancers: the experience of an integrated cancer prevention center.

Sella T, Boursi B, Gat-Charlap A, Aroch I, Liberman E, Moshkowitz M, Miller E, Gur E, Inbar R, Blachar A, Mabjeesh NJ, Rosenfeld O, Sperber F, Reiser V, Kleinman S, Jaffa AJ, Bloch M, Ormianer M, Naumov I, Kazanov D, Kraus S, Galazan L, Arber N.

Eur J Intern Med. 2013 Apr;24(3):245-9. doi: 10.1016/j.ejim.2012.12.012. Epub 2013 Jan 9.

PMID:
23312963
15.

Increased expression of CD24 in nonmelanoma skin cancer.

Miller E, Shapira S, Gur E, Naumov I, Kazanov D, Leshem D, Barnea Y, Meshiach Y, Gat A, Sion D, Arber N, Kraus S.

Int J Biol Markers. 2012 Dec 27;27(4):e331-6. doi: 10.5301/JBM.2012.9935.

PMID:
23250778
16.

Gene therapy of pancreatic cancer targeting the K-Ras oncogene.

Lisiansky V, Naumov I, Shapira S, Kazanov D, Starr A, Arber N, Kraus S.

Cancer Gene Ther. 2012 Dec;19(12):862-9. doi: 10.1038/cgt.2012.73. Epub 2012 Oct 26.

PMID:
23099885
17.

Novel approach to abuse the hyperactive K-Ras pathway for adenoviral gene therapy of colorectal cancer.

Naumov I, Kazanov D, Lisiansky V, Starr A, Aroch I, Shapira S, Kraus S, Arber N.

Exp Cell Res. 2012 Jan 15;318(2):160-8. doi: 10.1016/j.yexcr.2011.09.015. Epub 2011 Oct 12.

PMID:
22020090
18.

The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo.

Shapira S, Kazanov D, Weisblatt S, Starr A, Arber N, Kraus S.

J Biol Chem. 2011 Nov 25;286(47):40548-55. doi: 10.1074/jbc.M111.286534. Epub 2011 Oct 5.

19.

Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.

Sagiv E, Sheffer M, Kazanov D, Shapira S, Naumov I, Kraus S, Domany E, Arber N.

Digestion. 2011;84(3):169-84. doi: 10.1159/000322688. Epub 2011 May 5.

PMID:
21546775
20.

Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats.

Aroch I, Kraus S, Naumov I, Ron E, Shapira S, Kazanov D, Giladi N, Litvak A, Lev-Ari S, Hallak A, Dotan I, Shpitz B, Arber N.

Therap Adv Gastroenterol. 2010 Sep;3(5):281-9. doi: 10.1177/1756283X10379258.

21.

An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice.

Shapira S, Shapira A, Starr A, Kazanov D, Kraus S, Benhar I, Arber N.

Gastroenterology. 2011 Mar;140(3):935-46. doi: 10.1053/j.gastro.2010.12.004. Epub 2010 Dec 11.

PMID:
21147107
22.

First report of screening an asymptomatic population for cancer: the yield of an integrated cancer prevention center.

Boursi B, Guzner-Gur H, Mashich Y, Miler U, Gur E, Inbar R, Blachar A, Sperber F, Kleiman S, Yafo A, Elran H, Sella T, Naumov I, Kazanov D, Kraus S, Galazan L, Reshef N, Sion-Tadmor T, Rozen M, Liberman E, Moshkowitz M, Arber N.

Isr Med Assoc J. 2010 Jan;12(1):21-5.

23.

Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer.

Giladi N, Kazanov D, Shpitz B, Aroch I, Kraus S, Arber N.

Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S117-24. doi: 10.1517/13543781003718841.

PMID:
20374023
24.

Risk of colorectal neoplasia associated with the adenomatous polyposis coli E1317Q variant.

Hall MJ, Liberman E, Dulkart O, Galazan L, Sagiv E, Shmueli E, Kazanov D, Hallak A, Moshkowitz M, Figer A, Kraus S, Inbar M, Neugut AI, Arber N.

Ann Oncol. 2009 Sep;20(9):1517-21. doi: 10.1093/annonc/mdp023. Epub 2009 May 27.

25.

Malignant transformation of normal enterocytes following downregulation of Bak expression.

Liberman E, Naumov I, Kazanov D, Dvory-Sobol H, Sagiv E, Birkenfeld S, Deutsch V, Trakhtenbrot L, Moshkowitz M, Arber N.

Digestion. 2008;77(1):48-56. doi: 10.1159/000121411. Epub 2008 Mar 18.

PMID:
18349538
26.
27.

The APC E1317Q and I1307K polymorphisms in non-colorectal cancers.

Liberman E, Kraus S, Sagiv E, Dulkart O, Kazanov D, Arber N.

Biomed Pharmacother. 2007 Oct;61(9):566-9. Epub 2007 Sep 14.

PMID:
17920230
28.

Gene therapy approach in prostate cancer cells using an active Wnt signal.

Giladi N, Dvory-Sobol H, Sagiv E, Kazanov D, Liberman E, Arber N.

Biomed Pharmacother. 2007 Oct;61(9):527-30. Epub 2007 Sep 14.

PMID:
17904788
29.

Prospective assessment of microsatellite instability in gastrointestinal neoplasia in Ashkenazi and non-Ashkenazi Jews.

Strul H, Liberman E, Kariv R, Gartner M, Kazanov D, Keidar A, Carmeli Y, Degani Y, Halpern Z, Arber N.

J Med. 2003;34(1-6):139-48.

PMID:
17682319
30.

Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines.

Lev-Ari S, Kazanov D, Liberman E, Ben-Yosef R, Arber N.

Dig Dis Sci. 2007 Apr;52(4):1128-33. Epub 2007 Mar 7.

PMID:
17342386
31.

Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model.

Shpitz B, Giladi N, Sagiv E, Lev-Ari S, Liberman E, Kazanov D, Arber N.

Digestion. 2006;74(3-4):140-4. Epub 2007 Jan 15.

PMID:
17228149
32.

Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway.

Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N.

Cancer. 2007 Jan 15;109(2):188-97.

33.

Targeting the active beta-catenin pathway to treat cancer cells.

Dvory-Sobol H, Sagiv E, Kazanov D, Ben-Ze'ev A, Arber N.

Mol Cancer Ther. 2006 Nov;5(11):2861-71.

34.

CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis.

Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N.

Gastroenterology. 2006 Aug;131(2):630-9.

PMID:
16890615
35.

CD24 plays an important role in the carcinogenesis process of the pancreas.

Sagiv E, Kazanov D, Arber N.

Biomed Pharmacother. 2006 Jul;60(6):280-4. Epub 2006 Jun 23.

PMID:
16824727
36.
37.

Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway.

Dvory-Sobol H, Kazanov D, Arber N.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S370-4.

PMID:
16507412
38.

Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells.

Lev-Ari S, Zinger H, Kazanov D, Yona D, Ben-Yosef R, Starr A, Figer A, Arber N.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S276-80.

PMID:
16507392
39.

Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner.

Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, Benamouzig R, Arber N.

Eur J Cancer. 2006 Feb;42(3):422-6. Epub 2006 Jan 19.

PMID:
16426843
40.

Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells.

Stanhill A, Levin V, Hendel A, Shachar I, Kazanov D, Arber N, Kaminski N, Engelberg D.

Oncogene. 2006 Mar 9;25(10):1485-95.

PMID:
16278678
41.

Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells.

Lev-Ari S, Strier L, Kazanov D, Elkayam O, Lichtenberg D, Caspi D, Arber N.

Rheumatology (Oxford). 2006 Feb;45(2):171-7. Epub 2005 Oct 25.

PMID:
16249246
42.

Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.

Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N.

Clin Cancer Res. 2005 Sep 15;11(18):6738-44.

43.

MF tricyclic and sulindac retard tumor formation in an animal model.

Dvory-Sobol H, Kazanov D, Liberman E, Birkenfeld S, Bulvik B, Luk P, Leshno M, Arber N.

Int J Cancer. 2006 Jan 1;118(1):11-6.

44.

Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro.

Kazanov D, Dvory-Sobol H, Pick M, Liberman E, Strier L, Choen-Noyman E, Deutsch V, Kunik T, Arber N.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):267-71.

45.

The I1307K adenomatous polyposis coli gene variant does not contribute in the assessment of the risk for colorectal cancer in Ashkenazi Jews.

Strul H, Barenboim E, Leshno M, Gartner M, Kariv R, Aljadeff E, Aljadeff Y, Kazanov D, Strier L, Keidar A, Knaani Y, Degani Y, Alon-Baron L, Sobol-Dvory H, Halpern Z, Arber N.

Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1012-5.

46.

Oncogenic transformation of normal enterocytes by overexpression of cyclin D1.

Kazanov D, Shapira I, Pick M, Kolker O, Liberman E, Deutsch V, Strier L, Dvory-Sobol H, Kunik T, Arber N.

Dig Dis Sci. 2003 Jul;48(7):1251-61.

PMID:
12870780

Supplemental Content

Loading ...
Support Center